Retatrutide Guide: The Triple-Agonist GLP Research Compound

Published 2026-08-25 · Updated 2026-09-12 · Waifu Labs Research Library

Retatrutide — development code LY3437943 — is the compound that turned “GLP-3” into a household catalog term. It is a single 39-amino-acid peptide engineered to agonize three metabolic receptors at once: GLP-1, GIP and the glucagon receptor. That triple mechanism is why it outperformed earlier single- and dual-agonist compounds in published metabolic research, and why demand for lab-verified retatrutide has outpaced every other peptide in the category. This guide covers the mechanism, the headline study data, and what to verify before ordering retatrutide for research.

What retatrutide is

Retatrutide is a synthetic 39-residue peptide based on the human GIP backbone, acylated for once-weekly dosing intervals in study protocols and engineered to activate three receptors involved in metabolic regulation: GLP-1 (incretin satiety and insulin signaling), GIP (additional incretin pathway), and the glucagon receptor (hepatic metabolic activity). Eli Lilly developed it; published preclinical and clinical research runs under the code LY3437943. In research catalogs — including ours — it is commonly listed as “GLP3”, shorthand for the next generation of GLP-receptor research compounds.

Mechanism: why three receptors matter

Single-agonist GLP-1 compounds (semaglutide class) agonize one incretin receptor. Dual agonists (tirzepatide class) add the GIP receptor. Retatrutide adds glucagon-receptor agonism on top, producing activity across appetite regulation, insulin signaling and hepatic fat metabolism simultaneously in study models. The published Phase 2 obesity trial reported mean body-weight reductions of roughly 24% at 48 weeks at the highest studied dose — the deepest reduction reported to that date in a published trial of this class. Those figures are from controlled clinical research; they are what made the compound a research phenomenon, not a consumer product.

What purity means for a 39-residue peptide

Long peptides are synthesis-intensive: each additional residue is an opportunity for truncated sequences, deleted sequences or acylation errors. A 39-mer like retatrutide therefore demands the strictest QC in the catalog. Third-party HPLC at 99%+ quantifies truncated-sequence impurities, and mass spectrometry confirms the exact molecular weight — the two tests together are the only practical proof that a vial contains full-length retatrutide rather than a mixture of truncation products. This is why we treat retatrutide as a flagship for batch-specific COAs.

Storage and handling in the lab

Lyophilized retatrutide is stored at -20°C and is stable for 24+ months; the cold chain is the single biggest quality variable between supplier and bench. Vials should be allowed to reach room temperature before opening to prevent condensation uptake, reconstituted with bacteriostatic water for multi-day use in research settings, and the reconstituted solution kept at 2–8°C and used within roughly 30 days. Our stock ships from US-domestic warehouses with same-day dispatch on business-day orders placed before 2 PM EST, so vials spend days — not weeks — in transit.

Retatrutide vs tirzepatide in research catalogs

Tirzepatide (dual GLP-1/GIP agonist) is the approved comparator; retatrutide (triple agonist) is the next rung on the mechanistic ladder. Research buyers typically source both when the study design calls for a dose-response comparison across agonist generations. Waifu Labs stocks both as US-domestic peptides — GLP3 (Retatrutide) and Tirzepatide — in single-vial and 10-vial kit formats.

Frequently asked questions